Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma

被引:0
|
作者
Jun Nakashima
Yoshitaka Imaizumi
Hiroaki Taniguchi
Koji Ando
Masako Iwanaga
Hidehiro Itonaga
Shinya Sato
Yasuhi Sawayama
Tomoko Hata
Shinichiro Yoshida
Yukiyoshi Moriuchi
Yasushi Miyazaki
机构
[1] Nagasaki University Graduate School of Biomedical Sciences,Atomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology
[2] National Hospital Organization Nagasaki Medical Center,Department of Hematology
[3] Nagasaki University Hospital,Department of Hematology
[4] Sasebo City General Medical Center,Department of Hematology
[5] Nagasaki University Graduate School of Biomedical Science,Department of Frontier Life Science
来源
International Journal of Hematology | 2018年 / 108卷
关键词
ATL; Mogamulizumab; Prognostic factors;
D O I
暂无
中图分类号
学科分类号
摘要
Adult T-cell leukemia–lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood. We analyzed the associations of clinical factors with the outcome after Moga treatment. Forty-five patients treated with Moga monotherapy were evaluated. The median age of the patients was 69 years, and 40% were female. The median overall survival (OS) time was 17.6 months and the 2-year OS rate was 43.2%. Number of prior therapies and response to prior therapy were predictive clinical features in univariate analysis for OS. Performance status, corrected serum calcium level, serum lactate dehydrogenase level, Japan Clinical Oncology Group-prognostic index (PI), and simplified ATL-PI at Moga treatment were also associated with the prognosis after Moga monotherapy. Improved understanding of the clinical factors predicting the prognosis after Moga may contribute to improved treatment strategies for ATL.
引用
收藏
页码:516 / 523
页数:7
相关论文
共 50 条
  • [1] Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma
    Nakashima, Jun
    Imaizumi, Yoshitaka
    Taniguchi, Hiroaki
    Ando, Koji
    Iwanaga, Masako
    Itonaga, Hidehiro
    Sato, Shinya
    Sawayama, Yasuhi
    Hata, Tomoko
    Yoshida, Shinichiro
    Moriuchi, Yukiyoshi
    Miyazaki, Yasushi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (05) : 516 - 523
  • [2] Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma
    Winsett, Frank T.
    Lewis, Daniel J.
    Duvic, Madeleine
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (09) : 757 - 760
  • [3] ATYPICAL ADULT T-CELL LEUKEMIA-LYMPHOMA - DIVERSE CLINICAL MANIFESTATIONS OF ADULT T-CELL LEUKEMIA-LYMPHOMA
    SHIMOYAMA, M
    MINATO, K
    TOBINAI, K
    NAGAI, M
    SETOYA, T
    TAKENAKA, T
    ISHIHARA, K
    WATANABE, S
    HOSHINO, H
    MIWA, M
    KINOSHITA, M
    OKABE, S
    FUKUSHIMA, N
    INADA, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1983, 13 : 165 - 188
  • [4] Mogamulizumab Therapy for Adult T-Cell Leukemia-Lymphoma: A Retrospective Multicenter Study
    Tokunaga, Masahito
    Yonekura, Kentaro
    Nakamura, Daisuke
    Haraguchi, Kouichi
    Tabuchi, Tomohisa
    Nakano, Nobuaki
    Kubota, Ayumu
    Takeuchi, Shogo
    Takatsuka, Yoshifusa
    Yoshimitsu, Makoto
    Fujino, Satoshi
    Hayashida, Maiko
    Maekawa, Kenichi
    Arai, Akihiko
    Kamata, Yuhei
    Inoue, Hirosaka
    Owatari, Satsuki
    Otsuka, Maki
    Hanada, Shuichi
    Matsumoto, Tadashi
    Utsunomiya, Atae
    BLOOD, 2015, 126 (23)
  • [5] Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study
    Yonekura, Kentaro
    Kusumoto, Shigeru
    Choi, Ilseung
    Nakano, Nobuaki
    Ito, Asahi
    Suehiro, Youko
    Imaizumi, Yoshitaka
    Yoshimitsu, Makoto
    Nosaka, Kisato
    Ohtsuka, Eiichi
    Hidaka, Michihiro
    Jo, Tatsuro
    Sasaki, Hidenori
    Moriuchi, Yukiyoshi
    Ogata, Masao
    Tatetsu, Hiro
    Ishitsuka, Kenji
    Miyazaki, Yasushi
    Ueda, Ryuzo
    Utsunomiya, Atae
    Ishida, Takashi
    BLOOD ADVANCES, 2020, 4 (20) : 5133 - 5145
  • [6] Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma
    Ishitsuka, Kenji
    Yurimoto, Satoshi
    Tsuji, Yukie
    Iwabuchi, Manabu
    Takahashi, Takeshi
    Tobinai, Kensei
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (05) : 407 - 415
  • [7] CLINICAL DIVERSITY IN ADULT T-CELL LEUKEMIA-LYMPHOMA
    TAKATSUKI, K
    YAMAGUCHI, K
    KAWANO, F
    HATTORI, T
    NISHIMURA, H
    TSUDA, H
    SANADA, I
    NAKADA, K
    ITAI, Y
    CANCER RESEARCH, 1985, 45 (09) : 4644 - 4645
  • [8] ADULT T-CELL LEUKEMIA-LYMPHOMA
    YAMAGUCHI, K
    TAKATSUKI, K
    BAILLIERES CLINICAL HAEMATOLOGY, 1993, 6 (04): : 899 - 915
  • [9] ADULT T-CELL LEUKEMIA-LYMPHOMA
    NEELY, SM
    WESTERN JOURNAL OF MEDICINE, 1989, 150 (05): : 557 - 561
  • [10] Adult T-cell leukemia-lymphoma
    Tsukasaki, Kunihiro
    HEMATOLOGY, 2012, 17 : S32 - S35